Bliss GVS Pharma Limited

BSE: BLISSGVS506197ISIN INE416D01022

Healthcare
Pharmaceuticals
BSE Healthcare

Share price

₹625.60-12.30 (-1.93%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹744.75
52W low: ₹118.35
Off 52W high: -16.00%
1M return: -5.28%
3M return: +23.87%
6M return: +133.91%
1Y return: +306.63%
20D avg volume: 9,403
50 DMA: ₹657.24
200 DMA: ₹413.53

Key ratios Consolidated

Market cap: ₹6,652 Cr
Current price: ₹625.60
52W high / low: ₹744.75 / ₹118.35
Face value: ₹1.00
P/E: 39.95
P/B: 5.16
EPS (TTM): ₹15.66
Book value / share: ₹121.35
ROE: —
ROCE: 16.00%
Operating margin: —
Net margin: —
Debt / equity: 0.00
Net debt: ₹-32.21 Cr
Interest cover: 16.79
Dividend yield: 0.24%
Dividend / share (TTM): ₹1.50
Payout: 9.58%
Cash conversion cycle: 221.9 days

Financials

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24
Income statement
	313.37	285.58	256.99	218.25	244.40	207.47	197.99	210.42	217.68	183.64	198.13	200.72
	8.30	9.60	11.16	18.46	20.18	35.45	12.07	15.27	5.04	4.12	5.60	5.42
	321.67	295.18	268.15	236.71	264.58	242.92	210.05	225.68	222.72	187.76	203.73	206.14
	246.57	219.69	223.23	193.30	223.94	179.81	186.61	189.26	187.01	157.69	178.48	166.10
	135.82	94.64	111.26	86.22	95.37	93.41	76.61	97.41	100.01	98.48	87.28	90.97
	11.72	15.10	18.21	20.20	2.27	20.57	13.53	19.03	11.82	4.90	7.98	7.55
	44.99	43.05	36.14	35.94	33.35	31.00	28.24	29.76	27.51	26.54	24.51	24.29
	3.30	0.58	2.01	1.49	3.04	5.47	1.68	1.08	3.83	1.53	1.85	2.12
	10.50	9.94	8.67	8.35	8.26	8.20	8.04	7.55	6.98	6.85	6.85	6.95
	68.33	51.68	62.96	45.86	61.24	43.25	49.23	—	—	—	—	—
	75.10	75.48	44.92	43.41	40.63	63.11	23.44	36.42	35.71	30.07	25.25	40.05
	0.00	0.00	0.03	-2.51	0.00	0.00	0.00	0.00	0.00	0.00	-29.20	0.00
	75.10	75.48	44.95	40.90	40.63	63.11	23.44	36.42	35.71	30.07	-3.95	40.05
	21.76	24.11	7.95	16.12	12.04	18.75	6.79	10.62	10.01	7.97	0.96	10.97
	53.34	51.37	37.00	24.78	28.59	44.36	16.65	25.80	25.69	22.11	-4.91	29.07
	4.92	4.73	3.37	2.20	2.58	4.08	1.47	2.27	2.31	1.97	-0.88	2.64
Key metrics
	88.90	86.00	55.63	50.74	51.93	76.78	33.16	45.05	46.52	38.45	4.75	49.12
	28.40%	30.10%	21.60%	23.20%	21.20%	37.00%	16.70%	21.40%	21.40%	20.90%	2.40%	24.50%
	17.00%	18.00%	14.40%	11.40%	11.70%	21.40%	8.40%	12.30%	11.80%	12.00%	-2.50%	14.50%
	5.80%	—	3.70%	—	3.60%	—	2.20%	—	—	—	—	—
	28.20%	37.60%	29.80%	3.70%	12.30%	13.00%	-0.10%	4.80%	—	—	—	—
	86.60%	15.80%	122.20%	-4.00%	11.30%	100.60%	439.10%	-11.20%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	1,074	927.11	809.73	770.25	751.59	747.45
	47.52	73.53	36.49	28.74	17.79	31.49
	1,122	1,001	846.22	798.98	769.37	778.95
	882.79	808.57	720.58	652.91	663.30	651.19
	427.94	386.26	372.51	339.12	330.04	385.27
	65.23	61.25	49.28	51.35	44.34	34.91
	160.12	136.43	112.05	95.58	86.17	76.15
	7.38	12.01	8.12	6.91	10.36	4.74
	37.46	33.48	29.42	26.38	18.67	17.33
	228.83	201.58	157.30	—	—	161.98
	238.91	192.08	125.64	146.07	106.07	127.76
	-2.48	-2.49	0.00	-29.20	0.00	-73.59
	236.43	189.59	125.64	116.87	106.07	54.16
	69.94	54.86	35.38	35.29	29.34	31.04
	166.49	134.73	90.26	81.58	76.73	23.13
	15.22	12.23	8.02	7.23	6.83	1.46
Key metrics
	281.27	235.08	163.18	150.16	135.10	76.23
	26.18%	25.40%	20.20%	19.50%	18.00%	10.20%
	15.50%	14.50%	11.10%	10.60%	10.20%	3.10%
	—	16.00%	11.80%	—	—	—
	24.87%	14.50%	5.10%	2.50%	0.60%	—
	44.27%	49.30%	10.60%	6.30%	231.70%	—
	—	81.89	29.84	—	—	—
	—	1.03	1.17	—	—	—
	—	0.00	0.07	—	—	—
	—	-32.21	47.19	—	—	—
	—	221.9	222.1	—	—	—
Balance sheet
	—	1,492	1,301	—	—	—
	—	946.34	819.33	—	—	—
	—	35.14	23.79	—	—	—
	—	517.19	438.36	—	—	—
	—	150.73	125.73	—	—	—
	—	51.48	29.87	—	—	—
	—	450.68	397.01	—	—	—
	—	104.21	71.42	—	—	—
	—	235.54	171.72	—	—	—
	—	2.93	70.98	—	—	—
	—	2.93	51.13	—	—	—
	—	0.00	19.85	—	—	—
	—	1,232	1,092	—	—	—
Cash flow
	—	138.72	105.91	—	—	—
	—	-38.28	-75.44	—	—	—
	—	-89.21	-30.34	—	—	—
	—	56.83	76.07	—	—	—

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24
Income statement
	261.13	221.59	211.54	164.68	190.23	163.36	156.00	179.59	182.65	148.96	163.82	161.34
	7.44	8.76	9.30	10.23	25.84	10.59	9.36	11.66	8.35	6.84	8.46	7.90
	268.57	230.35	220.84	174.91	216.07	173.96	165.36	191.25	191.00	155.80	172.28	169.23
	211.28	179.14	177.04	147.11	182.61	143.39	151.01	161.48	167.11	129.65	146.43	140.71
	130.53	90.74	102.28	79.38	89.96	88.85	68.79	88.18	91.41	91.10	78.50	80.60
	0.00	0.00	7.79	0.00	0.00	0.00	0.00	—	—	—	—	—
	38.29	36.57	31.83	31.81	29.76	28.10	25.22	26.30	24.38	23.52	20.88	20.97
	1.12	0.39	1.81	1.48	2.71	5.11	1.30	0.67	3.45	1.17	1.53	1.79
	9.47	9.03	7.84	7.80	7.69	7.68	7.43	6.96	6.39	6.26	6.23	6.25
	52.15	42.41	38.14	27.67	47.23	30.85	39.07	4.96	3.44	1.78	10.86	4.40
	57.28	51.21	43.80	27.80	33.46	30.56	14.36	29.77	23.89	26.15	25.85	28.52
	41.09	0.00	0.36	-2.51	0.00	0.00	0.00	—	—	—	-41.09	—
	98.37	51.21	44.16	25.29	33.46	30.56	14.36	29.77	23.89	26.15	-15.23	28.52
	24.80	12.59	11.73	6.68	8.66	9.51	2.90	8.72	6.85	6.73	3.77	7.80
	73.57	38.62	32.42	18.61	24.79	21.05	11.45	21.05	17.04	19.42	-11.46	20.72
	6.93	3.65	3.06	1.76	2.35	2.00	1.08	2.00	1.63	1.85	-1.11	1.99
Key metrics
	108.96	60.63	53.81	34.57	43.86	43.35	23.09	37.40	33.73	33.58	-7.47	36.56
	41.70%	27.40%	25.40%	21.00%	23.10%	26.50%	14.80%	20.80%	18.50%	22.50%	-4.60%	22.70%
	28.20%	17.40%	15.30%	11.30%	13.00%	12.90%	7.30%	11.70%	9.30%	13.00%	-7.00%	12.80%
	7.80%	—	3.90%	—	3.20%	—	1.40%	—	—	—	—	—
	37.30%	35.60%	35.60%	-8.30%	4.20%	9.70%	-4.80%	11.30%	—	—	—	—
	196.80%	83.50%	183.10%	-11.60%	45.50%	8.40%	199.90%	1.60%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	858.94	729.81	667.21	605.46	598.34	636.36
	35.73	43.72	36.22	33.50	50.77	32.63
	894.67	773.53	703.42	638.96	649.11	668.99
	714.57	637.91	609.25	527.62	533.41	545.33
	402.93	360.46	339.47	305.83	293.66	350.83
	7.79	7.79	0.00	—	—	2.01
	138.50	121.50	99.42	82.59	72.54	65.06
	4.80	11.11	6.58	5.81	10.06	4.32
	34.14	31.02	27.05	23.52	15.17	13.85
	160.37	131.64	130.09	15.14	17.45	118.16
	180.09	135.62	94.17	111.34	115.69	123.66
	38.94	-2.16	0.00	-41.09	—	2.75
	219.03	133.47	94.17	70.26	115.69	126.40
	55.80	36.59	25.20	19.61	30.21	33.74
	163.22	96.87	68.97	50.65	85.48	92.66
	15.40	9.17	6.56	4.85	8.23	8.97
Key metrics
	257.97	175.60	127.80	99.59	140.92	144.57
	30.03%	24.10%	19.20%	16.40%	23.60%	22.70%
	19.00%	13.30%	10.30%	8.40%	14.30%	14.60%
	—	12.30%	9.20%	—	—	—
	24.63%	9.40%	10.20%	1.20%	-6.00%	—
	108.35%	40.50%	36.20%	-40.70%	-7.70%	—
	—	63.61	28.71	—	—	—
	—	1.27	1.41	—	—	—
	—	0.00	0.05	—	—	—
	—	-3.33	44.18	—	—	—
	—	236.0	246.1	—	—	—
Balance sheet
	—	1,344	1,220	—	—	—
	—	826.36	767.69	—	—	—
	—	3.33	6.83	—	—	—
	—	457.12	428.25	—	—	—
	—	110.92	81.94	—	—	—
	—	46.59	27.64	—	—	—
	—	419.34	367.66	—	—	—
	—	96.26	60.32	—	—	—
	—	168.59	124.55	—	—	—
	—	0.00	51.01	—	—	—
	—	0.00	31.34	—	—	—
	—	0.00	19.67	—	—	—
	—	1,155	1,059	—	—	—
Cash flow
	—	123.16	97.21	—	—	—
	—	-51.40	-77.73	—	—	—
	—	-75.37	-26.71	—	—	—
	—	59.55	68.50	—	—	—

Compounded growth

Standalone

Sales CAGR 3Y: +6.84%
Sales CAGR 5Y: —
Profit CAGR 3Y: +4.26%
Profit CAGR 5Y: —
Sales YoY (TTM): +24.63%
Profit YoY (TTM): +108.35%

Consolidated

Sales CAGR 3Y: +7.25%
Sales CAGR 5Y: —
Profit CAGR 3Y: +20.64%
Profit CAGR 5Y: —
Sales YoY (TTM): +24.87%
Profit YoY (TTM): +44.27%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 50.07%

Quarter	September 2026	June 2026
Promoter %	50.07%	35.01%

Holder	Type	Holding	Previous	Change
MATES VISA CONSULTANCY PRIVATE LIMITED	Promoter	47.95%	—	—
CLARUS CAPITAL I	Public	4.99%	3.51%	+1.48%
INVESTOR EDUCATION AND PROTECTION FUND AUTHORITY MINISTRY OF CORPORATE AFFAIRS	Public	2.46%	2.48%	-0.02%
ANUPAM RASAYAN INDIA LIMITED	Promoter	2.12%	—	—
360 ONE PIPE FUND	Public	1.99%	1.16%	+0.83%
COEUS GLOBAL OPPORTUNITIES FUND	Public	1.75%	1.75%	0.00%
LIFE INSURANCE CORPORATION OF INDIA	Public	1.53%	3.24%	-1.71%
GEE BEE SECURITIES PRIVATE LIMITED	Public	1.18%	—	—
AMIT ASHOK THAWANI	Public	1.06%	—	—
Anupam General Trading FZE	Promoter Group	0.00%	—	—
ARIL Fluorospeciality Private Limited	Promoter Group	0.00%	—	—
Tanfac Industries Limited	Promoter Group	0.00%	—	—
Doriath S.A.R.L	Promoter Group	0.00%	—	—
Anupam Japan GK	Promoter Group	0.00%	—	—
Kiran Pallavi Investments LLC	Promoter Group	0.00%	—	—

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%
Bliss GVS Pharma Limited	6,652	625.60	39.95	16.00%	+24.87% TTM	+44.27% TTM	+306.63%

Filings & corporate actions

Recent announcements

We wish to inform you that Asterisk Lifesciences Ltd, UK, a wholly owned subsidiary of Bliss GVS Pharma Limited, has obtained marketing authorization from the Medicines & Healthcare products ....4 Nov 2026 · Company Update / General
Please find enclosed herewith the Newspaper Publication regarding Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026.2 Nov 2026 · Company Update / Newspaper Publication
Please find enclosed herewith the outcome of Nomination and Remuneration Committee meeting held today i.e. on October 29, 2026, the members has granted 2,95,000 stock options under Bliss ....29 Oct 2026 · Company Update / General
Please find enclosed herewith the Outcome of Board Meeting which was held on today i.e. October 29, 202629 Oct 2026 · Board Meeting / Outcome of Board Meeting
Please find enclosed herewith the Outcome of Board Meeting which was held on today i.e. October 29, 202629 Oct 2026 · Board Meeting / Outcome of Board Meeting
Please find attached the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026.29 Oct 2026 · Result / Financial Results
Please find enclosed herewith the Newspaper Publication regarding the Postal Ballot Notice dated October 01, 2026.29 Oct 2026 · Company Update / Newspaper Publication
Please find enclosed herewith the Postal Ballot Notice dated October 01, 2026 ("Notice") alongwith the Explanatory Statement for seeking approval of the members of the Company by way of ....28 Oct 2026 · AGM/EGM / Postal Ballot
Bliss GVS Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/10/2026 ,inter alia, to consider and approve Pursuant to Regulation 29 ....22 Oct 2026 · Board Meeting / Board Meeting
Please find enclosed herewith the newspaper publication regarding the dispatch of Postal Ballot Notice.16 Oct 2026 · Company Update / Newspaper Publication
Please find enclosed herewith Postal Ballot Notice dated September 28, 2026 ("Notice") alongwith the Explanatory Statement for seeking approval of the members of the Company by way of remote ....15 Oct 2026 · AGM/EGM / Postal Ballot
We would like to inform you that the ESOP Allotment Committee at its meeting held today i.e. October 15, 2026 has approved the allotment of 53,500 equity shares of the face value of Re ....15 Oct 2026 · Company Update / Allotment of ESOP / ESPS
Please find enclosed herewith the disclosure under Regulation 31A (10) of the SEBI Regulations in relation to re-classification from the "promoter and promoter Group category" to the "public" category14 Oct 2026 · Company Update / General
Please find enclosed herewith the newspaper advertisement published regarding the Extension of Special Window for Re-Lodgement of Transfer Requests of Physical Shares.14 Oct 2026 · Company Update / Newspaper Publication
Please find enclosed herewith the certificate under Regulation 74(5) of SEBI(DP) Regulations, 2018 for the quarter ended September 30, 2026.6 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Catalyst Trusteeship Ltd6 Oct 2026 · Insider Trading / SAST / Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
Please find enclosed herewith the outcome of the Board Meeting held today i.e. Thursday, October 01, 2026 through Video Conferencing or Other Audio Visual Means.1 Oct 2026 · Board Meeting / Outcome of Board Meeting
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Anupam Rasayan India Ltd1 Oct 2026 · Insider Trading / SAST / Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
Please find enclosed herewith the Intimation for the Closure of the Trading Window w.e.f. Thursday, October 01, 2026.29 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Bliss GVS Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/10/2026 ,inter alia, to consider and approve Please find enclosed herewith ....28 Sep 2026 · Board Meeting / Board Meeting
Please find enclosed herewith the Outcome of the 2nd Board Meeting held on September 28, 2026 at shorter Notice regarding re-classification from the "Promoter and Promoter Group" category ....28 Sep 2026 · Company Update / Meeting Updates
Please find enclosed herewith the Outcome of the 1st Board Meeting held on September 28, 2026 at shorter Notice pursuant to the consummation of the transaction contemplated in the share ....28 Sep 2026 · Company Update / Meeting Updates
Please find enclosed herewith the Outcome of the Board Meeting held on September 28, 2026 pursuant to the Change in Control of the Company.28 Sep 2026 · Company Update / Change in Management Control
Please find enclosed herewith Outcome of Board Meeting held on September 28, 2026, pursuant to the consummation of the transaction contemplated in the share purchase agreement dated May 23, 2026.28 Sep 2026 · Others / Outcome without intimation
Please find enclosed herewith the outcome of the Postal Ballot along with the Scrutinizer''s Report and Voting Results.22 Sep 2026 · AGM/EGM / Postal Ballot
Please find enclosed herewith the Disclosure of Voting Results of the Postal Ballot along with the Scrutinizer''s Report.22 Sep 2026 · AGM/EGM / Postal Ballot
We would like to inform you that the ESOP Allotment Committee of the Company at its meeting held on today i.e. September 04, 2026 has approved the allotment of 55,250 equity shares of ....4 Sep 2026 · Company Update / Allotment of ESOP / ESPS
SBI Capital Markets Ltd ("Manager to the Open Offer") has submitted to BSE a copy of Post-Offer Advertisement in accordance with Regulation 18(12) of the Securities and Exchange Board of ....2 Sep 2026 · Company Update / General
Please find enclosed herewith the Newspaper Publication regarding the extension of the Special Window for Re-Lodgement of Transfer Request of Physical Shares.25 Aug 2026 · Company Update / Newspaper Publication
Please find enclosed herewith the Newspaper Publication regarding the publication of the advertisement for the Postal Ballot Notice.21 Aug 2026 · Company Update / Newspaper Publication
Please find enclosed herewith the Postal Ballot Notice ("Notice") dated August 12, 2026, alongwith the Explanatory Statement for seeking approval of Members of the Company by way of remote ....20 Aug 2026 · AGM/EGM / Postal Ballot
Please find enclosed herewith the copies of newspaper advertisement published regarding the extract of statement of Un-audited Standalone and Consolidated Financial Results of the Company ....14 Aug 2026 · Company Update / Newspaper Publication
Please find enclosed herewith the outcome of Members of the Nomination and Remuneration Committee of Bliss GVS Pharma Limited ("the Company")in its meeting held today i.e. on August 12, ....12 Aug 2026 · Company Update / General
We wish to inform you that the Board Meeting of the Company was held today i.e. on Wednesday, August 12, 2026 through Video Conferencing ("VC") / Other Audio Visual Means ("OAVM") with ....12 Aug 2026 · Result / Financial Results
We wish to inform you that the Board Meeting of the Company was held today i.e. on Wednesday, August 12, 2026, through Video Conferencing ("VC")/Other Audio-Visual Means ("OAVM"), with ....12 Aug 2026 · Board Meeting / Outcome of Board Meeting
We would like to inform you that the ESOP Allotment Committee of the Company at its meeting held today i.e. August 11, 2026 has approved the allotment of 31, 250 equity shares of the face ....11 Aug 2026 · Company Update / Allotment of ESOP / ESPS
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Life Insurance Corporation of India11 Aug 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Bliss GVS Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 ,inter alia, to consider and approve Pursuant to Regulation 29 ....5 Aug 2026 · Board Meeting / Board Meeting
SBI Capital Markets Ltd ("Manager to the Open Offer") has submitted to BSE a copy of Pre-Offer Advertisement in accordance with Regulation 18(7) of the Securities and Exchange Board of ....27 Jul 2026 · Company Update / General
Please find attached detailed intimation regarding resignation of Mr. Sachin Saboo, Senior Management Personnel of the Company, pursuant to Regulation 30 of SEBI (Listing Obligations and ....24 Jul 2026 · Company Update / Cessation

Corporate actions

Purpose	Ex date	Record date	Payment date
Final Dividend - Rs. - 1.0000	8 Jul 2026	8 Jul 2026	—
Interim Dividend - Rs. - 0.5000	18 Feb 2026	18 Feb 2026	—
Final Dividend - Rs. - 0.5000	24 Jul 2025	24 Jul 2025	—
Final Dividend - Rs. - 0.5000	18 Jul 2024	—	—

Board meetings

29 Oct 2026 Board Meeting - Financial Results
12 Aug 2026 Board Meeting - Financial Results